Amarin (AMRN), a few hours ago, received a body blow in the form of a controversial judgment from a Nevada judge that ruined the stock, decimated thousands of retail investor portfolios, shattered the reputation of scores of analysts, and gave a thumbs-up to a couple of freeloading generic companies which will now get a free ride on years of expensive and novel research done at Amarin.
Especially when the world is turning towards biopharma research to stop the novel coronavirus from destroying the world, this is a judgment against biopharma research and enterprise.
Yes, as